Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S, et al
FDA prescribing information for Mounjaro (tirzepatide) , the official label containing approved dosing, contraindications, and clinical trial data
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
Correct coding: D50.9 (iron deficiency anemia) N18.3 (CKD Stage 3) Incorrect coding: D63.1 (this would be denied) Other & Unspecified Anemia ICD-10 Codes (D64 Series) This category picks up all the leftovers, but you shouldnt use it casually
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy) and dual GIP/GLP-1 receptor agonists like tirzepatide (Mounjaro, Zepbound) are injectable medications used for type 2 diabetes management and weight loss
Subcutaneous protocols achieve peak plasma levels within 24 hours and maintain therapeutic concentrations for 1216 hours, which supports once-daily dosing
